Review: could Tysabri cause Progressive Multifocal Leukoencephalopathy?


Progressive multifocal leukoencephalopathy is found among people who take Tysabri, especially for people who are female, 40-49 old , have been taking the drug for 2 - 5 years, also take medication Baclofen, and have Multiple sclerosis . We study 139,605 people who have side effects while taking Tysabri from FDA and social media. Among them, 3,141 have Progressive multifocal leukoencephalopathy. Find out below who they are, when they have Progressive multifocal leukoencephalopathy and more.

You are not alone

Join a support group for people who take Tysabri and have Progressive multifocal leukoencephalopathy >>>

Personalized health information

On eHealthMe you can find out what patients like me (same gender, age) reported their drugs and conditions on FDA and social media since 1977. Our tools are free and anonymous. 86 million people have used us. 300+ peer-reviewed medical journals have referenced our original studies. Start now >>>


Tysabri has active ingredients of natalizumab. It is often used in multiple sclerosis. (latest outcomes from Tysabri 139,770 users)

Progressive Multifocal Leukoencephalopathy

Progressive multifocal leukoencephalopathy (rapidly progressive neuromuscular disease caused by opportunistic infection of brain cells) has been reported by people with apraxia, agitation, confusional state, jc virus infection, monoparesis (latest reports from 5,752 Progressive multifocal leukoencephalopathy patients).

On Aug, 27, 2016

139,605 people reported to have side effects when taking Tysabri.
Among them, 3,141 people (2.25%) have Progressive Multifocal Leukoencephalopathy

Number of reports submitted per year:

Could Tysabri cause Progressive multifocal leukoencephalopathy?

Time on Tysabri when people have Progressive Multifocal Leukoencephalopathy *:

  • < 1 month: 1.86 %
  • 1 - 6 months: 3.0 %
  • 6 - 12 months: 4.59 %
  • 1 - 2 years: 16.16 %
  • 2 - 5 years: 69.31 %
  • 5 - 10 years: 5.01 %
  • 10+ years: 0.08 %

Gender of people who have Progressive Multifocal Leukoencephalopathy when taking Tysabri *:

  • female: 68.93 %
  • male: 31.07 %

Age of people who have Progressive Multifocal Leukoencephalopathy when taking Tysabri *:

  • 0-1: 0.07 %
  • 2-9: 0.03 %
  • 10-19: 1.01 %
  • 20-29: 6.24 %
  • 30-39: 22.85 %
  • 40-49: 37.14 %
  • 50-59: 22.26 %
  • 60+: 10.4 %

Severity if Progressive Multifocal Leukoencephalopathy when taking Tysabri **:

  • least: 0.0 %
  • moderate: 0.0 %
  • severe: 0.0 %
  • most severe: 100 %

Top conditions involved for these people *:

  • Multiple Sclerosis (2,252 people)
  • Relapsing-Remitting Multiple Sclerosis (707 people)
  • Depression (171 people)
  • Muscle Spasticity (123 people)
  • Pain (109 people)

Top co-used drugs for these people *:

  • Baclofen (231 people)
  • Lyrica (117 people)
  • Avonex (104 people)
  • Neurontin (96 people)
  • Provigil (83 people)

* Approximation only. Some reports may have incomplete information.

** Reports from social media are used.

How to use the study: print a copy of the study and bring it to your health teams to ensure drug risks and benefits are fully discussed and understood.

Do you have Progressive multifocal leukoencephalopathy when taking Tysabri?

Browse all side effects of Tysabri

a b c d e f g h i j k l m n o p q r s t u v w x y z

Drugs that are associated with Progressive multifocal leukoencephalopathy

Progressive multifocal leukoencephalopathy

Could your condition cause Progressive multifocal leukoencephalopathy

Progressive multifocal leukoencephalopathy

Can you answer these questions?

More questions for: Tysabri, Progressive multifocal leukoencephalopathy

You may be interested in these reviews

More reviews for: Tysabri, Progressive multifocal leukoencephalopathy

NOTE: The study is based on active ingredients and brand name. Other drugs that have the same active ingredients (e.g. generic drugs) are NOT considered.

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only, and has not been supported by scientific studies or clinical trials unless otherwise stated. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

You may report adverse side effects to the FDA at or 1-800-FDA-1088 (1-800-332-1088).

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.